LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.54 -2.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.54

Max

1.55

Põhinäitajad
By Trading Economics
Sissetulek	13M -43M
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	17M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+72.9% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	3.2K 104M
Eelmine avamishind	4.07
Eelmine sulgemishind	1.54

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. aug 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15. aug 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15. aug 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15. aug 2025, 20:25 UTC

Tulu

Omandamised, ülevõtmised, äriostud

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15. aug 2025, 20:24 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 20:18 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15. aug 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15. aug 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15. aug 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15. aug 2025, 17:23 UTC

Market Talk

Tulu

Deere's Earnings Appear to Be Troughing -- Market Talk

15. aug 2025, 16:27 UTC

Tulu

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15. aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. aug 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15. aug 2025, 15:52 UTC

Omandamised, ülevõtmised, äriostud

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15. aug 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15. aug 2025, 15:29 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 15:29 UTC

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 15:28 UTC

Tulu

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15. aug 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15. aug 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15. aug 2025, 14:38 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15. aug 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15. aug 2025, 14:33 UTC

Omandamised, ülevõtmised, äriostud

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

72.9% tõus

12 kuu keskmine prognoos

Keskmine 2.68 USD 72.9%

Kõrge 4 USD

Madal 1.7 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.